Mesoblast (MEOB.F) Stock Overview

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details

MEOB.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 93.9% below our estimate of its fair value

Earnings are forecast to grow 62.65% per year

Earnings have grown 0.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

MEOB.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

US$21.53

69.4% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Mesoblast Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mesoblast
Historical stock prices
Current Share Price	AU$1.55
52 Week High	AU$2.59
52 Week Low	AU$0.96
Beta	0.85
1 Month Change	-2.52%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	109.77%
5 Year Change	-11.93%
Change since IPO	38.39%

Recent updates

Shareholder Returns

	MEOB.F	US Biotechs	US Market
7D	-2.5%	-4.0%	-2.3%
1Y	n/a	23.0%	17.1%

Return vs Industry: Insufficient data to determine how MEOB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MEOB.F performed against the US Market.

Price Volatility

Is MEOB.F's price volatile compared to industry and market?
MEOB.F volatility
MEOB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.7%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: MEOB.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MEOB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	81	Silviu Itescu	www.mesoblast.com

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

Mesoblast Limited Fundamentals Summary

How do Mesoblast's earnings and revenue compare to its market cap?
MEOB.F fundamental statistics
Market cap	US$2.09b
Earnings (TTM)	-US$94.37m
Revenue (TTM)	US$65.38m

31.9x

P/S Ratio

-22.1x

P/E Ratio

Is MEOB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEOB.F income statement (TTM)
Revenue	US$65.38m
Cost of Revenue	US$88.62m
Gross Profit	-US$23.23m
Other Expenses	US$71.14m
Earnings	-US$94.37m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.073
Gross Margin	-35.53%
Net Profit Margin	-144.33%
Debt/Equity Ratio	22.1%

How did MEOB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/07 09:51
End of Day Share Price	2026/03/02 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mesoblast Limited is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Stuart Roberts	Bell Potter
Matthew Prior	BofA Global Research

Mesoblast (MEOB.F) Stock Overview

Rewards

Risk Analysis

Looking to be second time lucky with a game-changing new product

Mesoblast Limited Competitors

Alvotech

IDEAYA Biosciences

Arcutis Biotherapeutics

AnaptysBio

Price History & Performance

Recent News & Updates

Mesoblast Limited Provides Revenue Guidance for Fiscal Year 2026

Mesoblast Limited Provides Data Presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for Blood and Marrow Transplant Research in Salt Lake City, Utah

Mesoblast Limited Announces Update on Ryoncil (remestemcel-L-rknd) for Pediatric SR-aGvHD and Plans for Adult Trials

Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of a Biologics License Application for its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain

Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of A Biologics License Application for Its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain

Mesoblast Limited Announces Changes to Board of Directors

Recent updates

Mesoblast Limited Provides Revenue Guidance for Fiscal Year 2026

Mesoblast Limited Provides Data Presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for Blood and Marrow Transplant Research in Salt Lake City, Utah

Mesoblast Limited Announces Update on Ryoncil (remestemcel-L-rknd) for Pediatric SR-aGvHD and Plans for Adult Trials

Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of a Biologics License Application for its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain

Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of A Biologics License Application for Its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain

Mesoblast Limited Announces Changes to Board of Directors

Mesoblast Limited Announces Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Mesoblast Limited Provides Revenue Guidance for the Quarter Ending December 31, 2025

Mesoblast And BMT CTN Initiate Pivotal Trial Of Ryoncil For Severe Acute GVHD In Adults

Mesoblast Limited Appoints James M. O’Brien as Chief Financial Officer

Mesoblast Limited to Meet with FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Mesoblast Limited, Annual General Meeting, Nov 25, 2025

Mesoblast Limited Receives J-Code from Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Mesoblast Limited Announces its Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin

Mesoblast Limited Announces Successful Commercial Launch of Ryoncil

Mesoblast Limited announced that it expects to receive AUD 76.8 million in funding

Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Mesoblast Limited Appoints Lyn Cobley to Its Board of Directors

Mesoblast Extends Payment Coverage for Ryoncil to over 100 Million USives

Mesoblast Provides an Update on Its Plans to Meet with the United States Food and Drug Administration to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure

Mesoblast Limited Announces That Ryoncil is Now Available for Purchase in the United States

Mesoblast Limited Announces Availability of RYONCIL Product Information in United States

Mesoblast Limited Announces Appointment of Dr. Gregory George to its Board of Directors

Mesoblast Limited Announces Approve Product Ryoncil® (Remestemcel-L)

Mesoblast Limited to Report First Half, 2025 Results on Feb 26, 2025

Mesoblast Limited Announces Ryoncil® Commercial Launch Update and Product Pipeline

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 260 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million.

Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy

FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)